Do No Harm: 0 High-Certainty Studies Support Pediatric Gender Drugs
Biopharma companies face a potentially shrinking market and tougher FDA standards after Senate testimony highlighted 'very low certainty evidence' for pediatric gender treatments. With systematic reviews failing to show robust benefit, pipeline programs and commercial prospects for puberty blockers and cross-sex hormones are at risk.